Skip to content
10-Q

Quarterly Report

BridgeBio Oncology Therapeutics, Inc. BBOT

0001213900-25-044424

← back to feed
Filed
May 15, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Current Liabilities Q1 2025 · Mar 31, 2025 $1.87M
Current Liabilities Q1 2025 · Dec 31, 2024 $187.52K
Total Liabilities Q1 2025 · Mar 31, 2025 $7.39M
Total Liabilities Q1 2025 · Dec 31, 2024 $5.71M
Current Assets Q1 2025 · Mar 31, 2025 $1.24M
Current Assets Q1 2025 · Dec 31, 2024 $1.95M
Total Assets Q1 2025 · Mar 31, 2025 $195.68M
Total Assets Q1 2025 · Dec 31, 2024 $194.42M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$618K
Stockholders Equity Q1 2025 · Mar 31, 2024 −$3.22M
Stockholders Equity Q1 2025 · Dec 31, 2023 −$63.57K
Sga Expense Q1 2025 · Mar 31, 2024 $66.7K
Net Income Q1 2025 · Mar 31, 2024 $1.1M
Operating Income Q1 2025 · Mar 31, 2024 −$66.7K